Derazantinib (ARQ-087) is an orally bioavailable, ATP-competitive inhibitor targeting fibroblast growth factor receptors (FGFRs) with low nanomolar potency. It is used in research to investigate FGFR-driven pathologies, demonstrating activity in both in vitro assays and in vivo tumor models.